安罗替尼二线治疗广泛期小细胞肺癌的临床疗效  

Clinical Efficacy of Anlotinib as Second-line Treatment on Patients with Extensive Small Cell Lung Cancer

作　　者：林建光[1] 陈平 解方为 蔡忠福 许天文[1] LIN Jianguang;CHEN Ping;XIE Fangwei;CAI Zhongfu;XU Tianwen(Department of Medical Oncology,The Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China;Department of Oncology,The 900th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army,Fuzhou 350001,China;Department of Oncology,The 910th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army,Quanzhou 362000,China)

机构地区：[1]福建医科大学附属第二医院肿瘤内科,泉州362000 [2]中国人民解放军联勤保障部队第九〇〇医院肿瘤科,福州350001 [3]中国人民解放军联勤保障部队第九一〇医院肿瘤科,泉州362000

出　　处：《肿瘤防治研究》2020年第12期953-957,共5页Cancer Research on Prevention and Treatment

摘　　要：目的观察分析安罗替尼二线治疗广泛期小细胞肺癌(SCLC)临床疗效及不良反应。方法回顾性分析30例广泛期SCLC患者的临床资料,上述患者一线化疗失败后拒绝二线化疗,自愿选择口服安罗替尼靶向抗肿瘤治疗,每两周期进行一次疗效评价,观察安罗替尼的不良反应。结果30例患者中完全缓解(CR)0例,部分缓解(PR)5例、疾病稳定(SD)17例、疾病进展(PD)8例。客观缓解率(ORR)为16.7%,疾病控制率(DCR)为73.3%,无进展生存期(PFS)为4.2月,总生存期(OS)为8.6月。最常见不良反应为疲劳乏力、高血压、厌食、体重减轻等,3/4级不良反应发生率为16.7%。结论安罗替尼二线治疗广泛期SCLC疗效较好,且大部分患者能够耐受不良反应。Objective To observe and analyze the clinical efficacy and adverse reaction of anlotinib as the second-line treatment on extensive small cell lung cancer.Methods We retrospectively analyzed the clinical data of the 30 patients with extensive small cell lung cancer.After the failure of the first-line chemotherapy,these patients rejected the second-line chemotherapy and voluntarily opted for oral targeted antitumor therapy with anlotinib.We evaluated the efficacy every two cycles and observed the adverse reaction.Results Among 30 patients,there was 0 case with CR,5 cases with PR,17 cases with SD and 8 cases with PD.ORR was 16.7%,DCR was 73.3%,PFS was 4.2 months and OS was 8.6 months.The most common adverse reaction was fatigue,hypertension,anorexia,weight loss,etc.The incidence of grade 3/4 adverse reaction was 16.7%.Conclusion Anlotinib as a second-line treatment for extensive small cell lung cancer has good curative effect and relatively low toxic side effects.

关 键 词：安罗替尼 广泛期 小细胞肺癌 二线 

分 类 号：R734.2[医药卫生—肿瘤]